SCHEMBL2270095

SCHEMBL2270095

O=C(Nc1cc(NCCCc2ccccc2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 7/20 0.55
KMT2A Q03164 4/20 0.52
PKM P14618 3/20 0.52
MEN1 O00255 3/20 0.52
MAPT P10636 2/20 0.52
GRIK1 P39086 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 1/20 0.51
KDM6B O15054 2/20 0.51
KDM4C Q9H3R0 2/20 0.51
PLK3 Q9H4B4 4/20 0.51
MCL1 Q07820 2/20 0.51
BCL2A1 Q16548 1/20 0.51
BCL2 P10415 1/20 0.51
KDM4E B2RXH2 1/20 0.49
ASPH Q12797 1/20 0.49
RIOX2 Q8IUF8 1/20 0.49
KDM8 Q8N371 1/20 0.49
LTC4S Q16873 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270389 0.93 KMT2A (0.55) PLK1KMT2APKMMEN1MAPT
SCHEMBL14429446 0.86 NPC1 (0.49) KMT2AMEN1TDP1NPC1RAB9A
SCHEMBL2273303 0.85 NPC1 (0.43) PLK1KMT2AMEN1NPC1RAB9A
SCHEMBL2272409 0.83 PLK1 (0.63) PLK1KMT2APKMMEN1MAPT
SCHEMBL2271236 0.83 PLK1 (0.60) PLK1KMT2APKMMEN1MAPT
SCHEMBL27696859 0.83 PLK1 (0.42) PLK1KMT2AMEN1TDP1NPC1
SCHEMBL4216999 0.81 KDM6B (0.51) KMT2AMEN1MAPTTDP1NPC1
SCHEMBL2275929 0.80 KMT2A (0.62) PLK1KMT2APKMMEN1MAPT
SCHEMBL2273929 0.78 NR1H4 (0.60) PLK1KMT2APKMMEN1MAPT
SCHEMBL610427 0.77 SYK (0.59) KMT2AMEN1MAPTTDP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 PLK1 4227/4885KMT2A 1669/4885PKM 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.